Dharini Sun, MD
Internal Medicine · Hamden, CTNPI 1558355743
Payments from drug & device makers
Across 116 payments — averaging $20.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$304
- Novo Nordisk$268
- Amgen$189
- Amarin Pharma, Inc.$179
- AbbVie$163
- GSK$120
- plus $1K from 26 others
What the payments were for
- Speaking & faculty fees$1687%
- Food & beverage$2,18393%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 17 | $304 |
| Novo Nordisk | 12 | $268 |
| Amgen | 8 | $189 |
| Amarin Pharma, Inc. | 11 | $179 |
| AbbVie(2 entities) | 8 | $163 |
| GSK | 6 | $120 |
| Pfizer | 6 | $114 |
| Sanofi | 1 | $110 |
| Johnson & Johnson(2 entities) | 4 | $82 |
| Scilex Pharmaceuticals Inc. | 3 | $76 |
| AstraZeneca(2 entities) | 4 | $75 |
| Endo Pharmaceuticals Inc. | 4 | $67 |
| Eisai Inc. | 3 | $56 |
| Boehringer Ingelheim | 3 | $55 |
| Sunovion Pharmaceuticals Inc. | 2 | $42 |
| E.r. Squibb & Sons, L.L.C. | 2 | $40 |
| Astellas Pharma US Inc | 2 | $39 |
| Merck | 2 | $39 |
| Acorda Therapeutics, Inc | 2 | $38 |
| Sanofi-aventis U.S. LLC | 2 | $38 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $36 |
| Currax Pharmaceuticals LLC | 2 | $34 |
| Amneal Pharmaceuticals LLC | 1 | $27 |
| UCB, Inc. | 1 | $26 |
| Neurocrine Biosciences, Inc. | 1 | $24 |
| Novartis | 1 | $18 |
| Ultragenyx Pharmaceutical Inc. | 1 | $18 |
| Avanir Pharmaceuticals, Inc. | 1 | $17 |
| Genentech USA, Inc. | 1 | $16 |
| Biohaven Pharmaceuticals, Inc. | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Seqirus USA Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TOUJEO$110
How this compares
$2,351 in reported general payments places this provider in the 85th percentile of 2,067 internal medicine providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 297 | $105,185 |
| MounjaroTirzepatide | 56 | $66,704 |
| OzempicSemaglutide | 49 | $65,034 |
| JardianceEmpagliflozin | 42 | $48,665 |
| LinzessLinaclotide | 53 | $33,672 |
| FarxigaDapagliflozin Propanediol | 76 | $33,234 |
| MyrbetriqMirabegron | 75 | $33,211 |
| TrulicityDulaglutide | 52 | $30,774 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 55 | $30,394 |
| EntrestoSacubitril/Valsartan | 85 | $27,854 |
| DovatoDolutegravir Sodium/Lamivudine | 14 | $23,947 |
| JanuviaSitagliptin Phosphate | 24 | $22,338 |
| TradjentaLinagliptin | 41 | $20,944 |
| XareltoRivaroxaban | 48 | $20,206 |
| Atorvastatin Calcium | 672 | $11,024 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $114 | $105,185297 claims |
| Lilly USA, LLCMounjaro, Trulicity | $304 | $97,477108 claims |
| Boehringer IngelheimJardiance, Tradjenta | $55 | $69,60983 claims |
| Novo NordiskOzempic | $268 | $65,03449 claims |
| AbbVieLinzess, Synthroid | $163 | $39,287118 claims |
| AstraZenecaFarxiga, Brilinta | $75 | $37,28294 claims |
| Astellas Pharma US IncMyrbetriq | $39 | $33,21175 claims |
| MerckJanuvia, Janumet | $39 | $31,71953 claims |
| GSKTrelegy Ellipta | $120 | $30,39455 claims |
| NovartisEntresto | $18 | $27,85485 claims |
| Johnson & JohnsonXarelto | $82 | $20,20648 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $27 | $6,720464 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,067 internal medicine providers in Connecticut.
Other internal medicine in Hamden
- Margaret ChusteckaHamden$652K
- Joseph SouferWaterbury$21.5M
- David RadinStamford$7M
- Steven RyderWestport$3.9M
- Nancy BrownNew Haven$2.8M
- Charles MontanoCromwell$2.8M
- Arthur DecillisMadison$1M
- Michelle MallitzTrumbull$971K
- Allen HellerWoodbridge$758K
- Gary BlickNorwalk$717K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.